<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02779634</url>
  </required_header>
  <id_info>
    <org_study_id>COENZYMEQ</org_study_id>
    <nct_id>NCT02779634</nct_id>
  </id_info>
  <brief_title>Ubiquinol Treatment in Patients With Heart Failure and Preserved Ejection Fraction</brief_title>
  <official_title>The Effect of Ubiquinol Treatment on Cardiac Function in Patients With Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are no studies specifically examining the effects of coenzyme Q (CoQ) treatment on
      echocardiographic indices of diastolic function in elderly patients with heart failure with
      preserved ejection fraction (HFPEF). In previous studies the only echocardiographic
      parameters studied were ejection fraction (EF) and chamber size. The objective of the
      proposed current study is to examine the effect of 16 weeks of ubiquinol therapy on diastolic
      function assessed by echocardiography in patients over the age of 50 with a clinical
      diagnosis of HFPEF. Ubiquinol (Kaneka Pharma), the reduced form of CoQ will be utilized for
      this study as it has been shown to have superior bioavailability when compared to oxidized
      CoQ.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in diastolic function as assessed by mitral valve inflow and tissue Doppler velocities on echocardiography</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>NT-pro brain natriuretic peptide (NT-proBNP) serum levels (pg/ml)</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pills of 100 mg ubiquinol three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ubiquinol</intervention_name>
    <description>Ubiquinol three times daily</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>coenzyme Q10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill three times daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Typical signs and symptoms of congestive heart failure (CHF) (New York Association
             Class 2-4).

          -  Normal ejection fraction on echocardiography (EF â‰¥50%).

          -  Evidence of diastolic dysfunction on non-invasive imaging (E:e' &gt; 15 or e:e' &gt; 8 with
             other measures of diastolic dysfunction such as e/a &lt; 0.5 with elevated deceleration
             time or left atrial volume index &gt; 40 cc/m2 or presence of elevated left ventricular
             mass index or elevated pulmonary pressures).

          -  Stable medical therapy for 4 weeks prior to randomization

        Exclusion Criteria:

          -  Chronic atrial fibrillation.

          -  Acute coronary syndrome or coronary revascularization within 60 days.

          -  Clinically significant valvular disease.

          -  Known infiltrative cardiomyopathy (e.g. amyloidosis), hypertrophic cardiomyopathy or
             chronic pericardial disease.

          -  Inability/refusal to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Leibowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara Elias</last_name>
    <email>sarae@hadassah.org.il</email>
  </overall_contact>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <last_update_submitted>May 18, 2016</last_update_submitted>
  <last_update_submitted_qc>May 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>LEIBOWITZ DAVID</investigator_full_name>
    <investigator_title>Associate professor of medicine Hadassah-Hebrew University Medical Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

